2026-09-17 · Fordyce Marshall (PRESIDENT AND CEO) · SELL
2026-09-17 · Fordyce Marshall (PRESIDENT AND CEO) · OTHER
2026-09-14 · Young Joseph R (SVP, FINANCE, CHIEF ACCT OFFCR) · OTHER
2026-09-04 · Fordyce Marshall (PRESIDENT AND CEO) · SELL
2026-09-04 · Fordyce Marshall (PRESIDENT AND CEO) · OTHER
INSTITUTIONAL OWNERSHIP
Institutional holders238
Shares held85,526,158
Value$3.49B
Percent of shares outstanding118.68%
As of quarter end2026-06-30
RECENT NEWS
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vera Therapeutics Announces ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgA Nephropathy Will be A Featured Late-breaking Oral Presentation at the Opening Plenary Session of ASN Kidney Week 2026
Vera Therapeutics presents at Morgan Stanley Global Healthcare Conference
Vera Therapeutics maintains hold rating after positive Trutakna data
Vera Therapeutics stock rises on new kidney drug trial results